RxSight (RXST) Cash & Equivalents (2020 - 2026)

RxSight's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $217.9 million for Q1 2026.

• Quarterly Cash & Equivalents fell 4.97% year-over-year to $217.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $217.9 million (down 4.97% YoY) and the FY2025 annual result came in at $228.1 million, up 1265.38% from the prior year.
• Cash & Equivalents was $217.9 million for Q1 2026 at RxSight, down from $228.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $233.2 million in Q2 2024 and bottomed at $16.7 million in Q4 2024.
• A 5-year average of $143.2 million and a median of $131.9 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents plunged 87.32% — and 2025, when it surged 1265.38%.
• RxSight's Cash & Equivalents stood at $105.8 million in 2022, then grew by 20.23% to $127.2 million in 2023, then tumbled by 86.87% to $16.7 million in 2024, then jumped by 1265.38% to $228.1 million in 2025, then slipped by 4.47% to $217.9 million in 2026.
• Business Quant data shows RXST's Cash & Equivalents at $217.9 million in Q1 2026, $228.1 million in Q4 2025, and $227.5 million in Q3 2025.